Project Grant R01HL173371
Award Date
7/15/25
Completion Date
4/30/30
Dollars Obligated
$852K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
This Project Grant award of $788,513 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on understanding the mechanisms underlying the maintenance of cardiac chamber identity in zebrafish. The research aims to elucidate the genetic pathways and signaling mechanisms that reinforce ventricular cardiomyocyte identity and suppress the transition to an atrial identity. Key objectives include identifying the downstream...
This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
This $1,102,500 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at the University of California, Los Angeles (UCLA) to address persistent problems in the field of intravascular triglyceride metabolism. The key focus areas include: Identifying sequences in apolipoprotein A5 (apoA5) that are important for suppressing the activity of the ANGPTL3/8 complex, and using that knowledge...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $194,375 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, Santa Barbara (UCSB) to study the impact of cardiomyopathy-driven extracellular matrix (ECM) remodeling on myocardial viscoelasticity and its effects on cardiomyocyte phenotype. The 24-month project aims to: 1) Determine how cardiomyopathy alters myocardial viscoelasticity, and 2) Assess how matrix viscoelasticity regulates...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The federal Project Grant award of $673,642 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of lysosomes in contributing to arrhythmic risk and sudden cardiac death in ischemic heart failure. The primary objectives are to: 1) Determine whether a lysosomal-sarcoplasmic reticulum (SR) microdomain exists in ischemic heart failure; 2) Evaluate whether TRPML1-mediated lysosomal Ca2+ release can trigger SR...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 "Cardiovascular Diseases Research" will provide $126,059 from September 1, 2024 to August 31, 2029 to the University of Colorado-Denver. The project aims to use proteomics and metabolomics approaches to study the systems biology of acute and chronic multi-organ failure in children with congenital heart disease (CHD). Specifically, the project will measure changes in the circulating...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $633,720 to The Washington University to conduct research on protein arginylation and its impact on cardiovascular health and development. The key objectives are to: Develop a chemical proteomics platform to comprehensively identify proteins that undergo arginylation in cardiac cells and tissues. This will involve mapping the "arginylome" and...